Primary Job Title CFO Primary Organization Harpoon Therapeutics
Gender Male
Mr. Picht joined Harpoon in January 2017 with more than 25 years of industry experience in strategic finance, operations, investor relations, business planning and oversight. Prior to Harpoon, he served as chief financial officer for Pearl Therapeutics, a respiratory disease company that was sold to AstraZeneca in a $1.15 billion transaction. At
Pearl, Mr. Picht was responsible for finance, administration and information technology. Previously, he served as head of R&D finance at Nektar Therapeutics, and conducted finance and market analytics at Syntex. Mr. Picht received his BA from the University of Notre Dame and his MBA from San Jose State University.
